Korean J Clin Pharm.  2015 Sep;25(3):171-177. 10.0000/kjcp.2015.25.3.171.

Retrospective Pharmacotherapeutic Evaluation of Dutasteride not Approved by US FDA for Androgenetic Alopecia in Korea

• Cheon YJ
• Kim JT
• Lim SC

• KMID: 2226409
• DOI: http://doi.org/10.0000/kjcp.2015.25.3.171

Abstract

BACKGROUND
Androgenetic alopecia (AGA), one of alopecias, requires continuous treatment in order to prevent or stop it, and patient's compliance is very important. Currently, only two drugs (finasteride, minoxidil) have been approved for AGA by Food and Drug Administration of United States (US FDA). However, another alpha-2 reductase inhibitor, dutasteride, is approved by Korea Ministry of Food and Drug Safety (MFDS) through a phase III trial. For treatment, pharmacotherapy of AGA usually combines topical minoxidil 7% with one of oral alpha-2 reductase inhibitor.
OBJECTIVES
We evaluated the comparative efficacy and adverse effect between topical minoxidil 7%/finasteride 1 mg and topical minoxidil 7%/dutasteride 0.5 mg pharmacotherapy for outpatients with AGA. Also we evaluated the relationship between therapeutic effect and regular hospital visit. METHOD: This study was performed retrospectively based on electronic medical record (EMR) data of total 98 patients (topical minoxidil 7% with dutasteride 0.5 mg (Avodart(R)) or finasteride 1 mg (Alopecia(R), Propecia(R)) with diagnosis of AGA from department of dermatology at a secondary hospital from January 1st, to May 31st, 2014.
RESULTS
The efficacy and adverse event of topical minoxidil 7%/dutasteride 0.5 mg (DUTA group) were 100% and 45.7%, and of topical minoxidil 7%/finasteride 1 mg (FINA group) were 92.1% and 33.3%, respectively. The mean onset time of responses and adverse events in the FINA group were 3.86 months and 4.43 months. Those in the DUTA group were 3.97 months and 5.06 months.
CONCLUSION
Both FINA and DUTA group were highly effective, but the DUTA group showed higher efficacy and adverse effects than those in the FINA group. Dutasteride may be another alternative in AGA treatment.

Keyword

alopecia; dutasteride; finasteride; minoxidil

MeSH Terms

Alopecia*
Compliance
Dermatology
Diagnosis
Drug Therapy
Electronic Health Records
Finasteride
Humans
Korea*
Minoxidil
Outpatients
Oxidoreductases
Retrospective Studies*
United States
United States Food and Drug Administration
Dutasteride
Finasteride
Minoxidil
Oxidoreductases